Lidocain is one of 148 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
105 competitors in Migraine
Avicel
Lidocain
Triptans
Aspirin /d
BAT7104
Flunarizine
Tizanidine Hydrochloride
Bayer Aspirin
Cymbalta
Adempas
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources